| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Clinical Pharmacology Branch [M. M. B., C. E. M., O. S., T. T., J. B. T.], and Medicine Branch [E. S.], National Cancer Institute, and Laboratory of Neuroscience [Y. S.], National Institute of Diabetes and Digestive and Kidney Diseases, NIH, Bethesda, Maryland 20892
The propensity of a cell to undergo apoptosis has been proposed to be a determinant for chemotherapy sensitivity that is not directly dependent on specific drug-target interactions. Androgen-independent prostate cancer is typically refractory to cytotoxic drugs, and we tested whether this is due to a loss of the ability to undergo apoptosis. Exposure of the hormone-insensitive and p53-negative human prostate carcinoma cell line PC-3 to 22 µM cisplatin, 1 µM camptothecin, 10 µM tenoposide, 135 nM vincristine, or 10 µM lovastatin for 72 h caused cell death, internucleosomal DNA fragmentation, and morphological changes typical for apoptosis. One µM cycloheximide prevented anticancer drug-induced apoptosis, whereas high concentration (1 mM) of cycloheximide alone induced apoptosis, indicating that protein synthesis was not needed for these cells to undergo apoptosis. Since cycloheximide affected DNA synthesis and proliferation of PC-3 cells, we tested whether the DNA polymerase inhibitor aphidicolin could also suppress drug-induced apoptosis. In contrast to cycloheximide, aphidicolin inhibited only vincristine-induced apoptosis. Cycloheximide prevented drug-induced changes in cell cycle distribution except for vincristine, while aphidicolin led to an accumulation of cells at the G1-S border independent of the drug used. These data indicate that macromolecular synthesis, active cell cycling, and p53 expression are not required for apoptosis to proceed in this system.
1 This research was supported by grants from the Swiss Cancer League (Bern Section) and the Swiss National Science Foundation (to M. M. B.).
2 To whom requests for reprints should be addressed, at Institute of Medical Oncology, University of Bern, Inselspital, CH-3010 Bern, Switzerland.
Received 12/ 5/94. Accepted 3/15/95.
This article has been cited by other articles:
![]() |
D. Pchejetski, N. Doumerc, M. Golzio, M. Naymark, J. Teissie, T. Kohama, J. Waxman, B. Malavaud, and O. Cuvillier Chemosensitizing effects of sphingosine kinase-1 inhibition in prostate cancer cell and animal models Mol. Cancer Ther., July 1, 2008; 7(7): 1836 - 1845. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. D. Flick, L. A. Habel, K. A. Chan, S. K. Van Den Eeden, V. P. Quinn, R. Haque, E. J. Orav, J. D. Seeger, M. C. Sadler, C. P. Quesenberry Jr., et al. Statin Use and Risk of Prostate Cancer in the California Men's Health Study Cohort Cancer Epidemiol. Biomarkers Prev., November 1, 2007; 16(11): 2218 - 2225. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Pchejetski, M. Golzio, E. Bonhoure, C. Calvet, N. Doumerc, V. Garcia, C. Mazerolles, P. Rischmann, J. Teissie, B. Malavaud, et al. Sphingosine Kinase-1 as a Chemotherapy Sensor in Prostate Adenocarcinoma Cell and Mouse Models Cancer Res., December 15, 2005; 65(24): 11667 - 11675. [Abstract] [Full Text] [PDF] |
||||
![]() |
M.-A. Shibata, Y. Ito, J. Morimoto, and Y. Otsuki Lovastatin inhibits tumor growth and lung metastasis in mouse mammary carcinoma model: a p53-independent mitochondrial-mediated apoptotic mechanism Carcinogenesis, October 1, 2004; 25(10): 1887 - 1898. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Somji, S. H. Garrett, M. A. Sens, V. Gurel, and D. A. Sens Expression of Metallothionein Isoform 3 (MT-3) Determines the Choice between Apoptotic or Necrotic Cell Death in Cd+2-Exposed Human Proximal Tubule Cells Toxicol. Sci., August 1, 2004; 80(2): 358 - 366. [Abstract] [Full Text] [PDF] |
||||
![]() |
M.-A. Shibata, C. Kavanaugh, E. Shibata, H. Abe, P. Nguyen, Y. Otsuki, J. B. Trepel, and J. E. Green Comparative effects of lovastatin on mammary and prostate oncogenesis in transgenic mouse models Carcinogenesis, March 1, 2003; 24(3): 453 - 459. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. C. Polek, L. V. Stewart, E. J. Ryu, M. B. Cohen, E. A. Allegretto, and N. L. Weigel p53 Is Required for 1,25-Dihydroxyvitamin D3-Induced G0 Arrest But Is Not Required for G1 Accumulation or Apoptosis of LNCaP Prostate Cancer Cells Endocrinology, January 1, 2003; 144(1): 50 - 60. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. Agarwal, B. Halmos, A. S. Feoktistov, P. Protiva, W. G. Ramey, M. Chen, C. Pothoulakis, J.T. Lamont, and P. R. Holt Mechanism of lovastatin-induced apoptosis in intestinal epithelial cells Carcinogenesis, March 1, 2002; 23(3): 521 - 528. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Park, I. Lee, and W. K. Kang Lovastatin-induced E2F-1 modulation and its effect on prostate cancer cell death Carcinogenesis, October 1, 2001; 22(10): 1727 - 1731. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Vitale, T. Di Matola, F. D'Ascoli, S. Salzano, F. Bogazzi, G. Fenzi, E. Martino, and G. Rossi Iodide Excess Induces Apoptosis in Thyroid Cells through a p53-Independent Mechanism Involving Oxidative Stress Endocrinology, February 1, 2000; 141(2): 598 - 605. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Kawabata, M. Hirokawa, A. Kitabayashi, T. Horiuchi, J. Kuroki, and A. B. Miura Defective Apoptotic Signal Transduction Pathway Downstream of Caspase-3 in Human B-Lymphoma Cells: A Novel Mechanism of Nuclear Apoptosis Resistance Blood, November 15, 1999; 94(10): 3523 - 3530. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Huang, C. P. Reed, J.-S. Zhang, V. Shridhar, L. Wang, and D. I. Smith Carboxypeptidase A3 (CPA3): A Novel Gene Highly Induced by Histone Deacetylase Inhibitors during Differentiation of Prostate Epithelial Cancer Cells Cancer Res., June 1, 1999; 59(12): 2981 - 2988. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. W. Choi and S. E. Jung Lovastatin-Induced Proliferation Inhibition and Apoptosis in C6 Glial Cells J. Pharmacol. Exp. Ther., April 1, 1999; 289(1): 572 - 579. [Abstract] [Full Text] |
||||
![]() |
F. P. Coxon, H. L. Benford, R. G. G. Russell, and M. J. Rogers Protein Synthesis Is Required for Caspase Activation and Induction of Apoptosis by Bisphosphonate Drugs Mol. Pharmacol., October 1, 1998; 54(4): 631 - 638. [Abstract] [Full Text] |
||||
![]() |
C. Guijarro, L. M. Blanco-Colio, M. Ortego, C. Alonso, A. Ortiz, J. J. Plaza, C. Diaz, G. Hernandez, and J. Egido 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase and Isoprenylation Inhibitors Induce Apoptosis of Vascular Smooth Muscle Cells in Culture Circ. Res., September 7, 1998; 83(5): 490 - 500. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Li, V. B. G. Segu, M. E. Rabaglia, R.-H. Luo, A. Kowluru, and S. A. Metz Prolonged Depletion of Guanosine Triphosphate Induces Death of Insulin-Secreting Cells by Apoptosis Endocrinology, September 1, 1998; 139(9): 3752 - 3762. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. J. Lee, M. J. Ha, J. Lee, P. Nguyen, Y. H. Choi, F. Pirnia, W.-K. Kang, X.-F. Wang, S.-J. Kim, and J. B. Trepel Inhibition of the 3-Hydroxy-3-methylglutaryl-coenzyme A Reductase Pathway Induces p53-independent Transcriptional Regulation of p21WAF1/CIP1 in Human Prostate Carcinoma Cells J. Biol. Chem., April 24, 1998; 273(17): 10618 - 10623. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Bian and Y. Sun p53CP, a putative p53 competing protein that specifically binds to the consensus p53 DNA binding sites: A third member of the p53 family? PNAS, December 23, 1997; 94(26): 14753 - 14758. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. J. Padayatty, M. Marcelli, T. C. Shao, and G. R. Cunningham Lovastatin-Induced Apoptosis in Prostate Stromal Cells J. Clin. Endocrinol. Metab., May 1, 1997; 82(5): 1434 - 1439. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |